Skip to Main Content

If you ask biotech investors today what they know about Arena Pharmaceuticals, nearly all will mention the weight-loss drug Belviq. Approved five years ago, it was touted as a potential blockbuster ― and ended up being a commercial flop.

Arena gave up on Belviq last January when it sold the rights to its Japanese partner, Eisai. Now, the company is developing three new drugs ― none of which has anything to do with obesity. The first in the pipeline, targeting a rare and debilitating lung disease, will read out study results later this month. With these new data, investors will get their first opportunity to assess Arena’s comeback strategy.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!